NDA 216540 · Bridgebio Pharma
Attruby
Acoramidis Hydrochloride · Oral
NovelOrphanCDER novel approval, Nov 22, 2024: To treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis
Last checked: Nov 19, 2026Latest source record: Nov 22, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Nov 22, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
12
6 Phase 3, 6 recruiting
FAERS reports
370
87 serious, 12 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 29, 2026.
ATTRUBY is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. ATTRUBY is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. ( 1 , 2.1 )
Mechanism: Acoramidis is a selective stabilizer of transthyretin (TTR). Acoramidis binds TTR at thyroxine binding sites and slows dissociation of the TTR tetramer into its constituent monomers, the rate-limiting step in amyloidogenesis.
Therapeutic areas: Cardiovascular and metabolic · Rare and genetic disease · Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ATTRUBY · ACORAMIDIS HYDROCHLORIDE EQ 356MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Acoramidis" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid CardiomyopathyPivotal-lookingCompleted
Eidos Therapeutics, a BridgeBio companyIndustry
NCT03860935 · 632 participants · Start Mar 19, 2019 · Primary completion May 11, 2023
Drug: acoramidis; Placebo Oral Tablet · For: Amyloidosis; Amyloid Cardiomyopathy; Transthyretin Amyloidosis and 2 more
Sites: Los Angeles, California; Santa Monica, California; Aurora, Colorado · 104 sites in all
- Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantPivotal-lookingRecruiting
Eidos Therapeutics, a BridgeBio companyIndustry
NCT06563895 · 587 participants (planned) · Start May 12, 2025 · Primary completion Oct 2031
Drug: Acoramidis; Placebo oral tablet · For: Amyloidosis; Amyloid Cardiomyopathy; Transthyretin Amyloidosis and 3 more
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 104 sites in all
- Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR ParticipantsPivotal-lookingActive, not recruiting
Eidos Therapeutics, a BridgeBio companyIndustry
NCT04988386 · 389 participants · Start Oct 27, 2021 · Primary completion Apr 15, 2028
Drug: Acoramidis (AG10) · For: Amyloid Cardiomyopathy, Transthyretin-Related
Sites: Los Angeles, California; Aurora, Colorado; Chicago, Illinois · 72 sites in all
- To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)Pivotal-lookingNot yet recruiting
Eidos Therapeutics, a BridgeBio companyIndustry
NCT07116473 · 250 participants (planned) · Start Nov 2026 · Primary completion Nov 2037
Drug: Acoramidis (AG10) · For: Amyloidosis in Transthyretin (TTR); Amyloidosis, Familial; Amyloid Cardiomyopathy and 7 more
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT07306949 · 200 participants (planned) · Start Oct 1, 2025 · Primary completion Mar 31, 2028
Drug: Acoramidis · For: Transthyretin-type Cardiac Amyloidosis
Sites: Bunkyō City, Japan; Kumamoto, Japan; Kurume-shi, Japan · 16 sites in all
Eidos Therapeutics, a BridgeBio companyIndustry
NCT07695701 · 150 participants (planned) · Start Jul 28, 2026 · Primary completion Aug 2030
Drug: Acoramidis (AG10) oral tablet · For: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM); Amyloidosis; Amyloid Cardiomyopathy and 1 more
Sites: Baltimore, Maryland; St Louis, Missouri; Philadelphia, Pennsylvania · 9 sites in all
BayerBayer (BAYRY)
NCT07298044 · 50 participants (planned) · Start Feb 13, 2026 · Primary completion Sep 17, 2027
Drug: Acoramidis · For: Transthyretin Amyloid Cardiomyopathy
Sites: Sankt Pölten, Austria; Vienna, Austria; Braunau am Inn, Austria · 26 sites in all
Eidos Therapeutics, a BridgeBio companyIndustry
NCT03536767 · 47 participants · Start Aug 8, 2018 · Primary completion Sep 15, 2025
Drug: Acoramidis · For: Amyloid Cardiomyopathy
Sites: San Francisco, California; Stanford, California; New Haven, Connecticut · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea69
- fatigue29
- dizziness23
- blood creatinine increased21
- abdominal discomfort18
- nausea18
- dyspnoea16
- weight decreased16
- asthenia15
- product dose omission issue15
- abdominal pain upper13
- rash11
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 189 |
| 2026 | 181 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Attruby (Acoramidis HCl)
2024 spending
$870K
Beneficiaries
41
41 claims
Per beneficiary
$21,220
$165.28 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $870,032 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy.
Gillmore JD, Judge DP, Cappelli F, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy.
Maurer MS, Judge DP, Gillmore JD, et al. · J Am Coll Cardiol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy.
Judge DP, Alexander KM, Cappelli F, et al. · J Am Coll Cardiol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial.
Judge DP, Gillmore JD, Alexander KM, et al. · Circulation 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Contemporary Oral Medication Use and Frequency in Patients with Transthyretin Amyloid Cardiomyopathy.
Dasgupta N, Poulsen SH, Emdin M, et al. · Am J Cardiovasc Drugs 2025 · Clinical Trial, Phase III, Multicenter Study
- Disease-Modifying Therapies for Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis.
Facin LC, Romeiro IPF, Sapahia K, et al. · Arq Bras Cardiol 2025 · Systematic Review, Meta-Analysis
Sponsor: Bridgebio Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.